Haemonetics Corporation
HAE
$78.71
$3.835.12%
NYSE
| 03/28/2026 | 12/27/2025 | 09/27/2025 | 06/28/2025 | 03/29/2025 | |
|---|---|---|---|---|---|
| Net Income | -145.03% | 15.66% | 13.67% | -41.31% | 54.64% |
| Total Depreciation and Amortization | -22.52% | -3.08% | -1.75% | 33.71% | -25.90% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 625.21% | -47.36% | 81.33% | 208.05% | -174.28% |
| Change in Net Operating Assets | -151.39% | -54.74% | 147.02% | -239.74% | 212.41% |
| Cash from Operations | -24.18% | -15.95% | 539.96% | -85.08% | 166.32% |
| Capital Expenditure | -178.17% | -26.57% | -33.62% | 76.00% | -83.04% |
| Sale of Property, Plant, and Equipment | 21.76% | 260.00% | -59.60% | -87.88% | 876.49% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 60.52% | 7.91% | 13.44% | -144.99% | -32.87% |
| Cash from Investing | -193.94% | 3.29% | 7.67% | -282.93% | 203.85% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -19,193.79% | -0.06% | 0.06% | 0.00% | -0.06% |
| Issuance of Common Stock | -96.76% | 5,884.13% | -98.40% | 2,712.86% | -96.05% |
| Repurchase of Common Stock | -62,428.75% | 99.79% | -1,469.00% | 96.81% | -33,307.57% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 7.14% | 64.10% | -8.33% | -33.33% | 81.88% |
| Cash from Financing | -5,092.57% | 102.66% | -3,034.81% | 98.39% | -11,074.64% |
| Foreign Exchange rate Adjustments | -193.33% | 204.79% | -118.48% | 50.97% | 144.59% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -276.17% | 1,797.42% | 125.45% | 1.55% | -165.31% |